Chapman Tripp has announced its involvement in a recent US$60 million capital raising round, which it says attracted investors from the likes of Mitsui, Warehouse founder Stephen Tindall's K1W1 fund, Siemens and more
Chapman Tripp has advised bio-fuels company LanzaTech on its recent US$60m capital raising round, which the firm says attracted new and existing investors including Mitsui, Siemens, Khosla Ventures, Warehouse founder Stephen Tindall's K1W1 fund, Qiming Venture Partners and the Malaysian Life Sciences Capital Fund.
Chapman Tripp has acted exclusively in New Zealand for LanzaTech since 2011, providing New Zealand legal advice to the company and its US-led legal team on both commercial and regulatory issues, including the Overseas Investment Act.
Partner Nick Wells and senior solicitor Greer Fredricson advised on the latest capital raising, which is the second round that the Chapman Tripp team has worked on for LanzaTech.
“This was a great result for LanzaTech, particularly in a market where capital at this level is hard to come by. We are delighted to play a continuing role in their success story,” says Wells.
“Typically these deals are led from the US and based on Silicon Valley standard documents, so our experience, combined with our local knowledge, means we are well placed to help New Zealand companies navigate the capital raising process,” he adds.
Chapman Tripp is advising on another Silicon Valley focused biotech capital raising, which the firm hopes to see announced soon.
Chapman Tripp has acted exclusively in New Zealand for LanzaTech since 2011, providing New Zealand legal advice to the company and its US-led legal team on both commercial and regulatory issues, including the Overseas Investment Act.
Partner Nick Wells and senior solicitor Greer Fredricson advised on the latest capital raising, which is the second round that the Chapman Tripp team has worked on for LanzaTech.
“This was a great result for LanzaTech, particularly in a market where capital at this level is hard to come by. We are delighted to play a continuing role in their success story,” says Wells.
“Typically these deals are led from the US and based on Silicon Valley standard documents, so our experience, combined with our local knowledge, means we are well placed to help New Zealand companies navigate the capital raising process,” he adds.
Chapman Tripp is advising on another Silicon Valley focused biotech capital raising, which the firm hopes to see announced soon.
